Serum Institutes of India’s Covovax gets panel nod for 12-17 age group

Serum Institute’s Covid-19 vaccine Covovax gets a panel nod from the government vaccine advisory body and it has been added to the national vaccination program for those aged 12 years and above. The Standing Technical Sub Committee (STSC) of the National Technical Advisory Group on Immunization received the recommendation to include the vaccine. The inclusion of use is for the vaccine in the 12-17 years age group in the national Covid-19 vaccination program, The Times Of India reported.

The company had requested the ministry to include its vaccine for the immunization of adolescents. After expanding the Covid-19 jabs, the NTAGI will submit the final recommendation to the country’s health ministry regarding the same. 

Earlier in December, Covovax has received restricted emergency use approval for adults in the age group 12-17. The recent decision has been taken by the government panel after a meeting with NTAGI on April 1. After this, it was recommended that the vaccine can be included in the national Covid-19 vaccination program for inoculating those aged 12 years and above.

Read Also: Covovax, Corbevax- India’s new approved vaccines; Know the efficacy, dosage, and difference between the vaccines

Vaccination of children aged 12-14 years in India started on March 16 and Biological Corbevax is being used to inoculate children. For the age group of 15-17, the vaccine Covaxine was used and it began in January. Moreover, Serum Institute of India (SII) director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, requesting Covovax’s inclusion in the immunization drive. This time, the company’s request to add the Covid-19 vaccine Covovax for 12-17 age group.